InsiderTrades.com logo
Biden’s Capital Gains Tax to Devastate Savings!
From Golden Crest   |   Ad
Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.
>> Get Your FREE Wealth Protection Guide <<

BCAX Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $34,254,000.00
Insider Selling (Last 12 Months): $0.00

Bicara Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Bicara Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bicara Therapeutics Share Price & Price History

Current Price: $25.30
Price Change: ▼ Price Decrease of -0.43 (-1.67%)
As of 09/19/2024 12:58 PM ET

This chart shows the closing price history over time for BCAX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Central Bank Abandons USD
From True Gold Republic   |   Ad
Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.
Click here now to get your free 'Protect Your Wealth' Guide.

Bicara Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/17/2024James E FlynnMajor ShareholderBuy70,000$18.00$1,260,000.00897,587View SEC Filing Icon  
9/16/2024Ra Capital Management, L.P.DirectorBuy1,833,000$18.00$32,994,000.004,303,418View SEC Filing Icon  
See Full Table
Central Bank Abandons USD
From True Gold Republic   |   Ad
Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.
Click here now to get your free 'Protect Your Wealth' Guide.

SEC Filings (Institutional Ownership Changes) for Bicara Therapeutics (NASDAQ:BCAX)

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Read More on Bicara Therapeutics

Today's Range

Now: $25.30
Low: $24.49
High: $26.11

50 Day Range

MA: N/A

52 Week Range

Now: $25.30
Low: $21.05
High: $27.94

Volume

205,546 shs

Average Volume

428,237 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Bicara Therapeutics?

Bicara Therapeutics' top insider shareholders include:
  1. Ra Capital Management, LP (Director)
  2. James E Flynn (Major Shareholder)
Learn More about top insider investors at Bicara Therapeutics.
Biden’s Capital Gains Tax to Devastate Savings!
From Golden Crest   |   Ad
Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.
>> Get Your FREE Wealth Protection Guide <<